T2 Biosystems Ink R&D Collaboration with Bayer
News Jul 18, 2016
T2 Biosystems, Inc. has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop tools and evaluate assays to help drive drug discovery and biomarker research for select Bayer hemostasis-related programs.
The sensitivity of T2MR in blood coagulation (hemostasis) research allows for the rapid and comprehensive monitoring of drug side effects in animal models and patients.
"We are very enthusiastic about our collaboration with Bayer and the important validation it represents for our T2MR technology in the field of hemostasis," said John McDonough, chief executive officer of T2 Biosystems. "Together with Bayer, we look forward to continuing the exploration of the clinical potential of our platform to provide improved patient care in this area of significant unmet need.”
The companies have been working together for the last year and recently extended the collaboration to include a number of pre-clinical and early clinical programs. This collaboration will enable T2 Biosystems and Bayer to evaluate the T2MR technology with the hemostasis drug discovery and development efforts at Bayer.
T2MR is a diagnostic detection method utilizing miniaturized magnetic resonance technology that measures how water molecules react in the presence of magnetic fields. The T2MR technology platform offers a fast, simple and sensitive alternative to existing diagnostic methodologies. T2MR technology powers all of the diagnostic innovation at T2 Biosystems and enables the detection of a variety of different targets including molecular targets, immunodiagnostics and a broad range of hemostasis measurements. Additionally, by incorporating the T2MR diagnostic platform into clinical trials, drug developers have the potential to dramatically enrich patient populations, which could result in decreased timelines and reduced cost of trials. Another key benefit to drug developers is the potential to have patients diagnosed rapidly enough to avoid courses of empiric therapy prior to the administration of the investigational drug, which could help to achieve clinical superiority.
About T2MR in Hemostasis
The first stage of wound healing, hemostasis, is a complex interaction of proteins and biochemical signals regulating the balance between bleeding and blood clotting. Patients with impaired hemostasis are either unable to promote the formation of blood clots to stabilize excessive bleeding or are hypercoaguable, with clots forming when they are not medically necessary. For hemostasis measurements, T2MR is highly sensitive to changes in viscosity in a blood sample (such as clot formation, stabilization or dissipation), which alter the magnetic resonance signal and enable identification of clinically relevant hemostasis changes. The T2MR-based hemostasis platform is being developed to provide a wide range of hemostasis diagnostics, including measurements of platelet activity, fibrinolysis and clotting time, directly from a blood volume not more than a finger stick amount of blood sample.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
Disease-Fighting 'Warheads' Hidden in BacteriaNews
Bacteria found in soil may harbor a potential game-changer for drug design. A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.READ MORE
Exploring Challenges in the Synthesis of Pharmaceutical DrugsNews
This summer, Wendell and Loretta Hess Professor of Chemistry Ram Mohan will travel to India and Hong Kong to deliver a series of post-graduate workshops on advanced concepts in organic synthesis.
His workshop “Advanced Concepts in the Synthesis of Pharmaceutical Drugs” at the Indian Institute of Technology Indore will explore the unique, real-world challenges in the pharmaceutical industry to synthesize drugs that are both commercially viable and eco-friendly.
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018